<DOC>
	<DOC>NCT02439970</DOC>
	<brief_summary>To compare the efficacy of brincidofovir (BCV) to valganciclovir (vGCV) for the prevention of cytomegalovirus (CMV) disease in kidney transplant allograft recipients who are CMV seronegative pretransplant and received a kidney from a CMV seropositive donor</brief_summary>
	<brief_title>SUSTAIN: A Randomized, Double-Blind, Multicenter, Phase 3 Study of the Efficacy, Safety, and Tolerability of Brincidofovir Versus Valganciclovir for the Prevention of Cytomegalovirus Disease in CMV Seronegative Kidney Allograft Recipients</brief_title>
	<detailed_description />
	<mesh_term>Cytomegalovirus Infections</mesh_term>
	<mesh_term>Valganciclovir</mesh_term>
	<mesh_term>Ganciclovir</mesh_term>
	<criteria>CMV seronegative recipient who received a kidney from a CMV seropositive donor First or second kidney transplant recipient Within 14 days post transplant, eGFR &gt; 10 mL/min by the CG equation Able to ingest tablets Multiorgan transplant recipient Plasma CMV PCR &gt;LOD by the central lab</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>kidney transplant allograft</keyword>
	<keyword>recipients</keyword>
</DOC>